BIO-RAD LABORATORIES, INC.

BIO 10-K · FY 2025
API behind this page

BIO FY 2025 request

Playground key active
Request URL /api/financials?ticker=BIO&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue From Contract With Customer Including Assessed Tax 2,583.2 2,566.5 +0.7%
Show Business Segments breakouts
Clinical Diagnostics [Member] 1,562.1 1,537.9 +1.6%
Life Science [Member] 1,021.1 1,028.1 -0.7%
Cost of Revenue 1,243.3 1,187.6 +4.7%
Show Business Segments breakouts
Clinical Diagnostics [Member] 775.3 741.3 +4.6%
Life Science [Member] 468 445.7 +5.0%
Gross Profit 1,339.9 1,378.9 -2.8%
Show Business Segments breakouts
Clinical Diagnostics [Member] 786.8 796.6 -1.2%
Life Science [Member] 553.1 582.4 -5.0%
Selling, General & Administrative 844.3 814 +3.7%
Show Consolidation Items breakouts
Material Reconciling Items · Interest Expense -844.3 -814 -3.7%
Research & Development 275.6 295.9 -6.9%
Show Consolidation Items breakouts
Material Reconciling Items · Interest Expense -275.6 -295.9 +6.9%
Impairment Of Intangible Assets Excluding Goodwill 172.8 — —
Show Consolidation Items breakouts
Material Reconciling Items 172.8 — —
Operating Income 47.2 269 -82.5%
Show Consolidation Items breakouts
Operating Segments 1,339.9 1,378.9 -2.8%
Interest Expense 49 48.9 +0.2%
Show Consolidation Items breakouts
Material Reconciling Items · Interest Expense -49 -48.9 -0.2%
Foreign Currency Transaction Gain Loss Before Tax -6.6 -3.9 -69.2%
Show Consolidation Items breakouts
Material Reconciling Items 6.6 3.9 +69.2%
Debt And Equity Securities Unrealized Gain Loss -900.4 2,656.8 -133.9%
Show Consolidation Items breakouts
Material Reconciling Items 900.4 -2,656.8 +133.9%
Other Non-Operating Income (Expense) -90.3 -90.3 0.0%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income 0.1 -1.6 +106.2%
Accumulated Net Unrealized Investment Gain Loss · Reclassification Out Of Accumulated Other Comprehensive Income -3.2 -2.2 -45.5%
Show Consolidation Items breakouts
Material Reconciling Items 90.3 90.3 0.0%
Income Before Taxes 995.5 -2,342.5 +142.5%
Income Tax Expense (Benefit) -235.6 498.3 -147.3%
Net Income 759.9 -1,844.2 +141.2%
Show Equity Components breakouts
Retained Earnings 759.9 -1,844.2 +141.2%
EPS (Basic) 27.87 -65.36 +142.6%
Wtd Avg Shares (Basic) 27,263 28,214 -3.4%
EPS (Diluted) 27.85 -65.36 +142.6%
Wtd Avg Shares (Diluted) 27,281 28,214 -3.3%
Revenue 2,583.2 2,566.5 +0.7%
Show Geography breakouts
Americas 165.4 169.3 -2.3%
Asia Pacific 513.3 521.6 -1.6%
Europe 881.8 834.1 +5.7%
US 1,022.7 1,041.5 -1.8%
Comprehensive Income 1,109 -2,046.4 +154.2%
Other Comprehensive Income 349.1 -202.2 +272.7%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 349.1 -202.2 +272.7%
Provision For Loan Lease And Other Losses 1.4 — —

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 529.8 488.1 +8.5%
Short-Term Investments 1,010.9 1,176.4 -14.1%
Accounts Receivable 460.6 452.5 +1.8%
Inventory 740.7 760 -2.5%
Prepaid Expense Current 136.5 122.6 +11.3%
Other Assets Current 27.7 30.7 -9.8%
Total Current Assets 2,906.2 3,030.3 -4.1%
Non-Current Assets
Property, Plant & Equipment 539.9 528.1 +2.2%
Operating Lease Right-of-Use Assets 170 160.5 +5.9%
Goodwill 579.8 410.5 +41.2%
Show Business Segments breakouts
Clinical Diagnostics [Member] 128.4 119 +7.9%
Life Science [Member] 451.4 291.5 +54.9%
Show Consolidation Items breakouts
Material Reconciling Items 579.8 410.5 +41.2%
Long Term Investments 6,103.6 4,839.2 +26.1%
Other Non-Current Assets 102.7 101.9 +0.8%
Total Assets 10,576.5 9,364.1 +12.9%
Show Business Segments breakouts
Clinical Diagnostics [Member] · Operating Segments 451.4 473.3 -4.6%
Life Science [Member] · Operating Segments 289.3 286.7 +0.9%
Show Consolidation Items breakouts
Operating Segments 740.7 760 -2.5%
Intangible Assets 174.3 100.9 +72.7%
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 7.9 7.3 +8.2%
Developed Technology Rights 155.8 75.1 +107.5%
Licensing Agreements 9.5 13.1 -27.5%
Noncompete Agreements 0.2 0.9 -77.8%
Trade Names 0.9 1.1 -18.2%
Other Assets
Intangible Assets Net Excluding Goodwill 174.3 293.6 -40.6%
Current Liabilities
Accounts Payable 129 122.3 +5.5%
Employee Related Liabilities Current 172.3 124.2 +38.7%
Notes And Loans Payable Current 1.3 1.2 +8.3%
Accrued Income Taxes Current 36.6 31.2 +17.3%
Operating Lease Liability Current 36.1 41.7 -13.4%
Other Liabilities Current 141.7 147.2 -3.7%
Total Current Liabilities 517 467.8 +10.5%
Deferred Revenue 48.9 47.8 +2.3%
Non-Current Liabilities
Long-Term Debt 1,201.7 1,200.4 +0.1%
Deferred Tax Liabilities 1,059.4 818 +29.5%
Operating Lease Liabilities 145.7 131.4 +10.9%
Other Non-Current Liabilities 199.1 177.2 +12.4%
Total Liabilities 3,122.9 2,794.8 +11.7%
Long-Term Debt 1,203 1,200.4 +0.2%
Show Debt Instrument breakouts
3.3%, Senior Notes due 2027 395.7 — —
3.7%, Senior Notes due 2032 790.5 — —
Other Long-Term Debt · Other Long-Term Debt 10 9.2 +8.7%
Senior Notes · Senior Notes 1,193 1,191.2 +0.2%
Stockholders' Equity
Additional Paid-In Capital 476 463.2 +2.8%
Treasury Stock Value -1,009.6 -772.1 -30.8%
Retained Earnings 8,176.3 7,416.4 +10.2%
Accumulated Other Comprehensive Income -189.1 -538.2 +64.9%
Total Stockholders' Equity 7,453.6 6,569.3 +13.5%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment 5.6 -1.8 +411.1%
Accumulated Gain Loss Net Cash Flow Hedge Parent 0.1 — —
Accumulated Net Unrealized Investment Gain Loss 11.7 4 +192.5%
Accumulated Other Comprehensive Income -189.1 -538.2 +64.9%
Accumulated Translation Adjustment -206.5 -540.4 +61.8%
Additional Paid In Capital 476 463.2 +2.8%
Retained Earnings 8,176.3 7,416.4 +10.2%
Treasury Stock Common -1,009.6 -772.1 -30.8%
Total Liabilities & Equity 10,576.5 9,364.1 +12.9%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Proceeds From Customers 2,656.4 2,553.1 +4.0%
Payments To Suppliers And Employees -2,058.9 -2,058.2 -0.0%
Interest Paid -46.6 -46.5 -0.2%
Income Taxes Paid -61.6 -99.4 +38.0%
Proceeds From Other Operating Activities 81 86.1 -5.9%
Proceedsfromderivativeinstrumentsoperatingactivities -38.1 20.1 -289.6%
Net Cash from Operations 532.2 455.2 +16.9%
Depreciation & Amortization 165.4 151.6 +9.1%
Show Business Segments breakouts
Clinical Diagnostics [Member] 90.4 84.3 +7.2%
Life Science [Member] 75 67.3 +11.4%
Stock-Based Compensation 58 62.3 -6.9%
Deferred Income Taxes 170.5 -626.8 +127.2%
Change in Accounts Receivable 19.6 16.2 +21.0%
Change in Inventory 68.9 8.5 +710.6%
Change in Other Liabilities -0.2 5.6 -103.6%
Investing Activities
Capital Expenditures -157.6 -165.6 +4.8%
Proceeds From Sale Of Property Plant And Equipment 0.1 0.1 0.0%
Payments For Previous Acquisition -218.5 — —
Payments To Acquire Investments -669.3 -1,276.6 +47.6%
Proceeds From Sale Of Available For Sale Securities Debt 793.6 1,106 -28.2%
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 62 199.3 -68.9%
Net Cash from Investing -189.7 -160.2 -18.4%
Financing Activities
Repayments Of Long Term Debt -0.5 -0.4 -25.0%
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 15.8 19.2 -17.7%
Tax Withholding for Share Compensation -3 -3.4 +11.8%
Share Repurchases -295.5 -203.6 -45.1%
Net Cash from Financing -283.2 -218.8 -29.4%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations -16.9 9.2 -283.7%
Net Change in Cash 42.4 85.4 -50.4%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 532.2 489.8 +8.7%
Restricted Cash Current 2 1.4 +42.9%
Restricted Cash Noncurrent 0.4 0.3 +33.3%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key